The T790M mutation in EGFR-mutant lung cancer exemplifies this mechanism, conferring resistance to first-generation inhibitors while sensitizing tumors to third-generation agents like osimertinib (OSI) [10,13]. Here, EGFR is linked to lung carcinoma.